Effects of heart disease on depression treatment: results from the COMED study

Area of Science:

• Psychiatry
• Cardiology
• Clinical Research

Background:

• Major depressive disorder (MDD) is a prevalent condition often comorbid with cardiovascular diseases.
• Understanding the impact of comorbidities like heart disease (HD) on treatment efficacy is crucial for personalized medicine.

Purpose of the Study:

• To investigate whether self-reported heart disease (HD) affects treatment outcomes for major depressive disorder (MDD).

Main Methods:

• A 7-month prospective randomized trial involving 665 participants with moderately severe MDD.
• Participants were randomized into three treatment arms: escitalopram/placebo, bupropion SR/escitalopram, or venlafaxine XR/mirtazapine.
• Remission was defined by specific QIDS-SR(16) scores, with response and side-effect burden as secondary outcomes.

Main Results:

• Participants with HD reported less depression at baseline and experienced fewer side effects.
• No significant differences were observed between groups with and without HD in terms of remission rates (40.0% vs. 38.2%).
• Response rates were also similar between the HD and non-HD groups (50% vs. 52.1%).

Conclusions:

• Self-reported heart disease did not alter major depressive disorder treatment outcomes.
• Despite baseline and side-effect variations, remission and response rates were comparable across groups.
• These findings suggest that MDD treatment strategies may not need to be significantly altered based solely on the presence of self-reported heart disease.